Status:
COMPLETED
Observational Study for Lung Cancer Patients Treated With Nivolumab
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France
Eligibility Criteria
Inclusion
- Male or female: 18 age at the time of nivolumab initiation
- Pathologically confirmed diagnosis of lung cancer
- Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study
Exclusion
- Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs
- Other protocol defined inclusion or exclusion criteria could apply
Key Trial Info
Start Date :
October 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 23 2020
Estimated Enrollment :
1462 Patients enrolled
Trial Details
Trial ID
NCT03382496
Start Date
October 1 2016
End Date
December 23 2020
Last Update
May 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Fontaine-lès-Dijon, France, 21121